Kairos Pharma Ltd. Common Stock (KAPA)

About KAPA

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant t…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

1

Website

kairospharma.com

Fundamentals

1-day range

$0.37$0.4056

Market cap

$8.35M

P/E (trailing)

—

P/E (forward)

-0.58

EPS (trailing)

$-0.30

Dividend yield

—

Beta

—

Avg. volume

2.19M

Forecasts

2 analyst ratings

Kairos Pharma Ltd. Common Stock Competitors

Chosen by industry and closest market cap.

• KAPA

  Kairos Pharma Ltd. Common Stock

  $0.237

  ▼ 1.66%
  Market cap $8.35MP/E —
  $0.27$2.11
• SNGX

  Soligenix Inc. Common Stock

  $0.38

  ▲ 0.00%
  Market cap $8.24MP/E —
  $0.28$3.22
• XCUR

  Exicure Inc. Common Stock

  $1.34

  ▼ 5.32%
  Market cap $8.60MP/E —
  $1.05$9.48
• LEXX

  Lexaria Bioscience Corp. Common Stock

  $10.35

  ▼ 11.39%
  Market cap $8.82MP/E —
  $4.21$23.25
• APRE

  Aprea Therapeutics Inc. Common stock

  $0.8387

  ▼ 2.48%
  Market cap $7.83MP/E —
  $0.548$1.69
• PCSA

  Processa Pharmaceuticals Inc. Common Stock

  $2.07

  ▼ 1.90%
  Market cap $7.65MP/E 3.31
  $1.67$14.24
• CNSP

  CNS Pharmaceuticals Inc. Common Stock

  $5.52

  ▲ 0.11%
  Market cap $7.65MP/E —
  $1.9$10.59

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

537.2K

Total value held

$293.8K

Institutional holders

10